Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.19.2
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Research and development:    
Compensation and benefits $ 2,578 $ 5,604
Material manufacturing costs 1,232 1,162
Consultants and outside services 674 651
Facilities and other 534 1,962
Total research and development 19,079 17,280
General and administrative:    
Compensation and benefits 4,286 6,684
Facilities and other 1,193 1,337
Professional fees 841 762
Investor relations 500 317
Total general and administrative 6,820 9,100
Impairment of long-lived assets 33 1,691
Loss on sale of property and equipment 12 663
Total operating expenses 25,944 28,734
Operating loss (25,944) (28,734)
Non-operating income (expense):    
Interest expense (4,958) (689)
Loss on extinguishment of debt 0 (602)
Gain on change in fair value of embedded derivatives 74 26
Gain on lease termination 168 0
Rental income 153 136
Interest and other income 61 1
Total non-operating income (expense) (4,502) (1,128)
Net loss (30,446) (29,862)
Net loss attributable to common stockholders $ (32,719) $ (29,862)
Net loss per common share - basic and diluted $ (0.37) $ (0.54)
Weighted average number of common shares outstanding - basic and diluted 88,872 55,655
License    
Research and development:    
Cost of goods and services sold $ 14,026 $ 6,273
Clinical trial costs    
Research and development:    
Cost of goods and services sold $ 35 $ 1,628